医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

TIELLE® Non Adhesive Foam Dressing Now Available from Acelity

2015年05月19日 PM04:00
このエントリーをはてなブックマークに追加


 

SAN ANTONIO

Acelity, a global wound care and regenerative medicine company, today announced that TIELLE® Non Adhesive, a new and improved foam dressing, is now available in Europe. TIELLE® Non Adhesive is the first in an enhanced range of TIELLE® hydropolymer foam dressings incorporating new design and materials to better meet patient needs and help provide a comfortable and effective healing environment for all types of wounds.

The TIELLE® Non Adhesive, part of the TIELLE® Family range, is intended to manage a range of exudate levels, while retaining more fluid than other foam dressings. The result is a cover dressing that is more comfortable and easier for a patient to wear. The TIELLE® Non Adhesive dressing is a polyurethane foam dressing that can be cut to size, and is designed to help maintain a moist wound healing environment through the combination of superior fluid handling, moisture vapor transmission and flexibility. The design allows up to seven days wear time without leakage, depending on the level of exudate. This may significantly reduce the number of dressing changes.

“This is a significant opportunity for Acelity to apply our deep expertise in advanced wound care and reassert TIELLE® as the market leader in the foam dressing category,” said Joe Woody, president and CEO of Acelity. “In the coming months, we will be introducing four additional innovative options within the TIELLE® range to meet specific patient needs. Our goal at Acelity is to continue building upon our industry-leading position to offer clinicians solutions for the most difficult wounds to heal.”

TIELLE® Non Adhesive dressing is composed of three layers: the original LiquaLock® absorbent layer, which locks fluid away to reduce the risk of maceration and leakage, even under movement and pressure exerted by compression bandaging1, a new superabsorbent layer that enhances fluid handling capacity1, and a new highly breathable polyurethane film backing, which also works as a bacterial barrier2. The new design and materials together maximize performance, leading to a 30 percent increase in Total Fluid Handling Capacity (TFHC)1 and a dressing 40 percent thinner than the previous version. Responding to customer feedback, the dressings are provided in transparent primary packaging, to aid product selection.

Acelity is focused on changing the practice of medicine with transformative technology and providing innovative healing solutions that restore patient lives. TIELLE® Non Adhesive is currently available in Europe. To learn more, please visit: www.Systagenix.com/TielleNA.

About Acelity

Acelity is a global wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. We are committed to advancing the science of healing and restoring people’s lives. Available in more than 75 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,500 people around the world. We believe in enabling better futures for everyone. Please visit acelity.com.

References

1. Stephens, S. et al. Evaluation of the performance of a non-adhesive foam dressing for the management of wound exudate. Poster, SAWC Spring 20152

2. Data on file bacterial barrier testing.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150519005373/en/

CONTACT

Acelity
Cheston Turbyfill, +1-210-515-7757
Corporate
Communications
cheston.turbyfill@acelity.com
or
Caleb
Moore, +1-210-255-6433
Investor Relations
caleb.moore@acelity.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent